Asana BioSciences, LLC to P rovide First Presentation of Pre - C linical Data on its N ovel ERK 1/2 Inhibitor P rogram at the American Association for Cancer Research Annual Meeting / by TI

Bridgewater, New Jersey, April 14, 2016 – Asana BioSciences, LLC announced today that it will present preclinical data regarding its product candidate, ASN007A, at the American Association for Cancer Research (AACR) Annual Meeting, being held in New Orleans, Louisiana, from April 16-20, 2016. The presentation details are as follows:

Abstract Number:  187  
Title:   ASN007, a potent ERK 1/2 inhibitor with strong antitumor activity in multiple RAS mutant models  
Presenter: Sanjeeva Reddy, Ph.D., Asana BioSciences
Location:  Section 7, Poster Board Number 12  
Date:  Sunday, April 17, 2016  
Times:  1:00pm – 5:00pm

ERK kinases play a crucial role in RAS/MAPK pathway, which is upregulated in a wide variety of tumors through mutations in RAS or BRAF genes. ERK inhibitors are expected to treat a wide range of tumors with BRAF, MEK, NRAS, HRAS and KRAS mutations including colorectal, pancreatic, lung, breast, ovarian, melanoma and prostate. In addition, they have potential to overcome resistance to BRAF and MEK inhibitors in patients.

ASN007A is one of the lead compounds from Asana’s ERK 1/2 inhibitor program with low nanomolar IC50 values. It showed strong anti-proliferative activity in both BRAF and RAS mutant cell lines, as well as potent anti-proliferative activity in a number of KRAS, NRAS and HRAS mutant cell lines representing various histological tumor types. It demonstrated strong inhibition of tumor growth in multiple xenograft models in mice and was well tolerated at efficacious doses. Based on its profile in preclinical studies, ASN007A is a potential best-in-class molecule expected to show strong efficacy in BRAF and various RAS mutant cancers.

About Asana BioSciences, LLC

Asana BioSciences, LLC, an independent member of the Amneal Alliance of Companies, is a research and development company based in Bridgewater, New Jersey, specializing in the discovery and development of new chemical and biological entities.  Asana’s portfolio consists of multiple early-stage development candidates in a variety of therapeutic areas, including oncology, pain and inflammation, among others. Asana’s other lead molecules, ASN001 (CYP17 inhibitor for prostate cancer) and ASN002 (dual SYK-JAK inhibitor for non-Hodgkin’s lymphoma and solid tumors), are currently in Phase I/II clinical studies in the United States. Several other molecules in Asana’s portfolio are currently in the late stages of preclinical development.

Roger Smith, Ph.D. Vice President                    
T:   908-698-0839